Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Precision Multiple Antigen T Cell
- Development stage
- Phase 2
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Subcutaneous
01
Overview
Precision Multiple Antigen T Cell is a type of immunotherapy that utilizes T cells engineered to target multiple common tumor-associated antigens. This cell therapy is designed to enhance the immune system's ability to recognize and eliminate cancer cells. It is often investigated in conjunction with dendritic cells, forming what is referred to as dendritic cell-precision multiple antigen T cells (DC-PMAT). The therapy aims to improve treatment outcomes in various advanced cancers, including hepatocellular carcinoma and gastric cancer with liver metastasis, by specifically targeting tumor cells. Clinical trials are evaluating its safety and efficacy, often in combination with other treatments like transcatheter arterial chemoembolization or as an adjuvant therapy after radical surgery.
- Other names
- DC-PMATdendritic cell-precision multiple antigen T cells
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on Precision Multiple Antigen T Cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Precision Multiple Antigen T Cell.